Press release
Biotage Introduces New Microwave Peptide Synthesizer Delivering
The Biotage Initiator+ SP Wave is a versatile synthesis solution as it can be used as a standalone peptide synthesizer or easily converted to a high specification MAOS system. It is the ideal development tool for chemists synthesizing peptides, peptidomimetics and small molecules using single or multi-step procedures.
The Initiator+ SP Wave is perfectly suited for the small scale synthesis of peptides and peptidomimetics including PNA using microwave irradiation, from a scale as low as 5 µmol. The semi-automated operation can reduce the consumption and waste of expensive reagents which occur in other systems due to priming or use of large dead volumes.
The Initiator+ SP Wave is a semi-automated, programmable synthesis system. It includes a large 10” touch screen, intuitive software, pre- or self-defined methods, inert gas capability, vortex and magnetic stirring.
“As the global leader in the development of technology for peptide synthesis, Biotage continues to develop tools for professionals demanding excellent purity, reliability and high yield.” says Toshiyuki Yachi, Vice President of Marketing. “With the recent introduction of the Initiator Peptide Workstation and Syro Wave, Biotage now offers a manual, semi-automatic and fully automatic peptide synthesis solution including resins and HPLC columns. Biotage is clearly the dedicated leader in providing solutions for peptide professionals.”
Biotage is the only manufacturer of traditional, room temperature peptide synthesizers as well as microwave peptide synthesizers in both entry-level and high throughput configurations. For more information on the Biotage Initiator+ SP Wave system, please email product_info@biotage.com or visit http://www.biotage.com/peptides.
About Biotage®
Biotage® offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. Customers include the world’s largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK and Japan. Biotage has 272 employees with sales of 428.9M SEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange.
Contact:
Rob Thompson
Director of Marketing Communications
Biotage
10430 Harris Oaks Blvd., Suite C, Charlotte, NC USA 28269
Tel: 704-654-4900
E-Mail: rob.thompson@biotage.com
Web: http://www.biotage.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biotage Introduces New Microwave Peptide Synthesizer Delivering here
News-ID: 183274 • Views: …
More Releases from Biotage
Biotage® Announces EVOLUTE® EXPRESS Columns - Simplified, Fast and Efficient S …
Uppsala, Sweden -- Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, announces the addition of new polymer based SPE columns to their tried and tested EVOLUTE® EXPRESS range.
EVOLUTE® EXPRESS is a novel family of plates, and now columns, that simplify polymer-based SPE by employing a streamlined three step protocol; Load-Wash-Elute. By using this approach and removing the conditioning and equilibration steps, necessary…
Biotage Launches ACI™ - Accelerated Chromatographic Isolation
Uppsala, Sweden (July 10, 2014) -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of ACI™ (Accelerated Chromatographic Isolation), a new advance converting simple flash purification into a faster and more economical way to isolate pure compounds.
Biotage believes that ACI™ will radically improve the efficiency of the laboratory, embracing the latest developments in purification technology to guide chemists…
Biotage Breaks New Ground with Its Fully Integrated Mass Directed Flash System
Uppsala, Sweden, June 5, 2013 -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of the new Isolera™ Dalton - a fully automated miniaturized mass directed flash purification system. The new system raises the bar for flash purification by integrating, for the first time, a miniaturized mass detector and an advanced flash chromatography system into one commercially available…
More Releases for Peptide
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market …
Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).
[https://www.skyquestt.com/report/peptide-therapeutics-market] size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
